Most interesting;
‘The Phase 2 trial will be in 26 patients using a two stage Simons MinMax Design. If at least three pCRs are observed in the first 11 patients, then the Phase 2 trial expands to another 15 patients. For the purposes of this analysis, two pCRs have already been observed in the first five patients.’
In a great place to be already for the Phase 2a study it seems.
